What is CTLA-4? The immune system normally uses a protein called CTLA-4 (cytotoxic T lymphocyte antigen-4) as a brake on T cells - the immune cells that attack foreign invaders and cancer. When CTLA-4 is activated on a T cell's surface, it sends a signal to slow the immune response down. This is a healthy regulatory mechanism that prevents the immune system from attacking the body's own healthy tissue.
CTLA-4 in cancer: In cancer, however, tumors can exploit this same mechanism. By triggering CTLA-4 activity, tumors can effectively put the brakes on the immune response, shielding themselves from destruction. Elevated CTLA-4 activity has been observed in several cancer types, including colorectal cancer (CRC), suggesting that CTLA-4 plays a meaningful role in how these tumors survive and grow.
Why genetic variations matter: The gene that codes for CTLA-4 contains several known variants - places in the DNA sequence where one person's code differs from another's. These variants, called single nucleotide polymorphisms (SNPs), can influence how much CTLA-4 protein is made, how efficiently it works, or how it interacts with other immune molecules. Studying these variants can help researchers understand why some individuals are more susceptible to cancer than others.
The research gap in Saudi Arabia: While CTLA-4 SNPs have been studied in European and Asian populations, little was known about their relationship to colorectal cancer risk specifically in Saudi Arabian patients. This study aimed to fill that gap by examining three well-characterized CTLA-4 SNPs in 100 Saudi CRC patients and 100 healthy controls.
CRC as a global and regional burden: Colorectal cancer is among the most common cancers worldwide and a leading cause of cancer-related deaths. Globally, it ranks third in incidence and second in cancer mortality. In Saudi Arabia alone, there were 4,007 new colorectal cancer cases in 2021, representing 14.4% of all cancers reported in the country that year.
Challenges in treatment: While chemotherapy and targeted therapies have improved survival for patients with advanced CRC, major obstacles remain - including drug resistance and serious side effects, often driven by tumor heterogeneity. This has pushed researchers toward immunotherapy approaches, which harness the body's own immune system to fight cancer.
Why study genetic markers? Cancer arises from a combination of environmental exposures and genetic predispositions. SNPs - small differences in the DNA code between individuals - can subtly alter gene function and affect immune response. Studying SNPs in genes like CTLA-4 that regulate the immune system may reveal which patients carry higher risk and could benefit from preventive screening or targeted immunotherapy.
What makes this study unique: Saudi Arabia's population has a distinct genetic background compared to European and Asian populations that have been more extensively studied. Additionally, consanguineous (within-family) marriages are relatively common in Saudi society, which affects how genetic variants are distributed across the population. This study is the first to examine the link between CTLA-4 polymorphisms and CRC specifically in Saudi patients.
Study population: This was a case-control study conducted at King Khalid University Hospital. A total of 200 participants were enrolled: 100 patients with sporadic (non-hereditary) colorectal cancer and 100 healthy controls with no cancer history. All participants were Saudi Arabian. The patient group included 64 males and 36 females with an average age of about 56 years. Controls were matched by age and sex to make the comparison fair.
Patient disease stage: CRC patients covered multiple disease stages: about 57% were in early stages (I and II), and 32% were in later stages (III and IV). Tumor locations included the colon (40 patients) and recto-sigmoid region (60 patients). Importantly, none of the patients had undergone chemotherapy or radiation before blood samples were collected, which avoided any treatment-related effects on gene expression.
The three SNPs studied: Three specific CTLA-4 variants were selected for genotyping based on prior evidence that they affect gene function. These are: rs11571317 (located in the gene's promoter region, which controls gene activity), rs231775 (a coding variant in exon 1 that changes an amino acid in the protein), and rs3087243, known as CT60 (located in the 3' UTR, which affects mRNA stability and protein levels).
Genotyping technology: DNA was extracted from blood samples and genotyped using TaqMan allelic discrimination assays - a highly reliable fluorescence-based method that can identify which version of each SNP a person carries. Five different inheritance models (co-dominant, dominant, recessive, over-dominant, and log-additive) were tested to comprehensively assess each variant's relationship to CRC risk.
The rs231775 variant (+49A>G): This is a coding SNP that changes a single amino acid in the CTLA-4 protein, potentially altering how effectively it functions. The study found that the G allele of this variant was significantly more common in CRC patients than in healthy controls (54% vs. 33%), with an odds ratio of 2.34 - meaning individuals with this allele were more than twice as likely to develop CRC. The GG genotype was especially striking: it was present in 47% of cancer patients but only 5.2% of controls, carrying odds ratios of 8.93 (co-dominant model) and 16.32 (recessive model).
The rs3087243 variant (CT60 G>A): This variant sits in a regulatory region that influences how much CTLA-4 protein is ultimately produced. The AA genotype was found in 35% of cancer patients compared to 14.1% of controls, with a significant odds ratio of 3.32. The A allele overall was also associated with increased CRC risk (OR = 1.82). These findings suggest that higher CTLA-4 production driven by this variant may help tumors evade immune surveillance.
The rs11571317 variant (-658C>T): Unlike the other two variants, this promoter region SNP showed no statistically significant association with CRC risk in any of the five inheritance models tested. This negative finding is itself informative, suggesting that not all CTLA-4 variants carry equal weight in CRC susceptibility.
Interpreting the numbers: The odds ratios for rs231775 in particular are remarkably large for a genetic study, suggesting this variant has a substantial effect on CRC risk - at least in this Saudi population. These results remained significant even after applying the strict Bonferroni statistical correction to account for multiple comparisons.
What is haplotype analysis? Rather than looking at each genetic variant in isolation, haplotype analysis examines combinations of variants that tend to be inherited together on the same chromosome. This can reveal risk patterns that individual variant analysis might miss, since genes don't act alone - the combination of variants a person carries can matter more than any single one.
Five common haplotypes identified: The researchers identified five common haplotypes formed by the three CTLA-4 SNPs, which together accounted for more than 90% of the genetic patterns observed in this study population. The most common haplotype (A-G-G) was used as the reference for comparison.
The G-A-G haplotype - a striking finding: One haplotype, designated G-A-G (referring to the alleles at rs11571317, rs231775, and rs3087243 respectively), was found exclusively in colorectal cancer patients - not a single healthy control carried it. Statistically, this was associated with a 57.66-fold higher risk of developing CRC (95% CI: 6.82 to 487.84, p = 3 x 10^-4). While the wide confidence interval reflects the relatively small sample size, the signal is nonetheless striking.
What this means biologically: The G-A-G haplotype likely represents an especially unfavorable combination of CTLA-4 regulatory and functional effects - potentially producing too much CTLA-4 or a form of it that is particularly effective at suppressing T cell activity. This would give tumors a stronger ability to hide from immune detection. This finding points to the value of haplotype analysis over single-variant studies for identifying high-risk individuals.
Gene expression analysis: Beyond genotyping, the researchers also measured how much CTLA-4 mRNA (the molecular messenger that carries instructions for making the protein) was present in actual tumor tissue versus normal adjacent colon tissue. RNA was extracted from 31 cancer tissue samples and 30 matched normal samples from CRC patients.
Striking overexpression in tumors: The analysis revealed that CTLA-4 mRNA levels were approximately 5 to 6 times higher in tumor tissue compared to normal colon tissue (mean values of 5.4 versus 0.30, with p < 0.001). This is a large, statistically robust difference that strongly suggests CTLA-4 plays an active functional role within the tumor environment.
Protein confirmation by immunohistochemistry: To confirm these findings at the protein level, the researchers also performed immunohistochemistry - a technique that uses antibodies to visually stain for a specific protein in tissue sections. Strong CTLA-4 protein staining (appearing brown under the microscope) was confirmed in cancer tissues compared to the much weaker staining seen in normal tissue. Interestingly, early-stage tumors (stages I and II) showed stronger staining than later-stage tumors, suggesting CTLA-4 expression may be particularly important in early tumor development.
Biological significance: These expression findings are consistent with CTLA-4's role as an immunosuppressive molecule. By expressing high levels of CTLA-4, colorectal tumors may be actively suppressing the immune cells that would otherwise attack them. This makes CTLA-4 not just a genetic risk factor, but also a potential functional target for cancer immunotherapy in CRC.
The story of CTLA-4 blockade: The discovery that blocking CTLA-4 activity can unleash the immune system against cancer earned James Allison a share of the 2018 Nobel Prize in Medicine. Ipilimumab, the first approved CTLA-4 blocking antibody, has shown dramatic results in some cancer types, most notably melanoma. The question of whether this approach could work for colorectal cancer has been an active area of research.
What this study adds: By demonstrating that specific CTLA-4 genetic variants are associated with increased CRC risk - and that CTLA-4 protein is markedly overexpressed in CRC tumors - this study builds a compelling case that the CTLA-4 pathway is biologically relevant in colorectal cancer. This matters because it suggests CRC patients with certain CTLA-4 genotypes might derive particular benefit from CTLA-4 blocking immunotherapy.
Potential as a screening biomarker: If validated in larger studies, the rs231775 and rs3087243 variants - and especially the G-A-G haplotype - could potentially serve as screening markers to identify Saudi individuals at elevated genetic risk for CRC. This could enable earlier surveillance and prevention efforts in high-risk individuals before cancer develops.
Limitations to keep in mind: The study's 200-participant sample is relatively small for genetic association studies, and its findings are specific to the Saudi population. Larger replication studies across diverse populations will be needed before these markers can be considered for clinical use. The authors themselves note that further validation in a larger Saudi cohort is an essential next step.
Summary of findings: This study demonstrated for the first time that CTLA-4 genetic variants are associated with colorectal cancer risk in the Saudi population. Two of the three variants studied (rs231775 and rs3087243) showed statistically significant associations with CRC, and one haplotype combination (G-A-G) was found exclusively in cancer patients. At the protein level, CTLA-4 expression was 5 to 6 times higher in tumor tissue than in normal colon tissue, confirming its biological relevance in the disease.
A first step for a unique population: Because the Saudi population has a distinct genetic makeup - shaped in part by historical patterns of consanguineous marriages - findings from European or Asian studies cannot simply be extrapolated. This work provides the foundation for population-specific risk assessment tools that could be more accurate for Saudi patients.
The path forward: The authors call for larger studies to validate these findings before CTLA-4 SNPs can be considered for clinical use as screening markers. They also emphasize the need to further investigate how these variants mechanistically affect CTLA-4 expression and T cell activity in the context of CRC. Understanding this biology could illuminate new targets for immunotherapy and help refine patient selection for existing CTLA-4 blocking treatments.
Broader context: This work is part of a growing recognition that immune checkpoint genes - the molecular gatekeepers of immune response - play a critical role in cancer susceptibility and progression. As immunotherapy continues to revolutionize cancer treatment, studies like this one help define which patients are most likely to benefit and why.